# Taysha Gene Therapies Inc. (TSHA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.73B  
**Price:** $5.40 (+0.75%)

> Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $10M | — | -$110M | -$109M | $-0.34 |
| 2024 | $8M | — | -$91M | -$89M | $-0.36 |
| 2023 | $15M | — | -$72M | -$112M | $-0.96 |
| 2022 | $3M | — | -$162M | -$166M | $-3.78 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $343M | $96M | $247M | $320M | $50M |
| 2024 | $160M | $89M | $72M | $139M | $44M |
| 2023 | $173M | $98M | $75M | $144M | $41M |
| 2022 | $126M | $125M | $949,000 | $88M | $38M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$93M | $738,000 | -$94M |
| 2024 | -$81M | $374,000 | -$82M |
| 2023 | -$73M | $4M | -$77M |
| 2022 | -$88M | $21M | -$109M |
| 2021 | -$117M | $15M | -$132M |
| 2020 | -$31M | $82,000 | -$31M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TSHA)